Stock vs Stock Comparison

Becton, Dickinson and Company vs Abbott Laboratories

ABT wins the Tale of the Tape 5–4.

BDX$158.17
ABT$100.68

🏆 Tale of the Tape

45
BDXABT
7.7%Profitability (Net Margin)14.7%
27.9xValuation (P/E)27.7x
4.2%Efficiency (ROIC)10.1%
7/9Health (Piotroski F)5/9
1.9Safety (Altman Z)4.9
8.2%Growth (Rev YoY)5.7%
0.47Risk (Sharpe 1Y)-0.98
1.18xBalance Sheet (D/E)0.64x
4.41%FCF Yield4.18%

Green = winner in each category. Higher is better except P/E (lower = cheaper).

Rolling Correlation

0.386
252-Day Correlation
0.438
126-Day Correlation

Moderately correlated — some diversification benefit from holding both.

Fundamentals

MetricBDXABT
Market Cap$43.6B$175.4B
P/E Ratio27.9x27.7x
Forward P/E11.8x16.6x
P/B1.81x3.35x
Dividend Yield2.63%0.03%
Beta0.270.61

Quantitative Metrics

MetricBDXABT
DCF Fair Value$350.06$67.82
DCF Upside+121.3%-32.6%
Piotroski F7/95/9
Altman Z1.864.89
Beneish M-2.63-2.53
FCF Yield4.41%4.18%
Net Debt/EBITDA3.4x0.1x
ROIC4.2%10.1%
WACC6.8%8.4%
ROIC – WACC-2.6pp1.7pp
Gross Margin45.4%56.4%
Net Margin7.7%14.7%
Rev Growth YoY8.2%5.7%
Sharpe (1Y)0.47-0.98
Max Drawdown 3Y
FCF Payout Ratio45%56%

BDX Price

Loading chart...

ABT Price

Loading chart...

ETF Exposure

BDX found in:

IHI4.63%
XHE1.67%
NOBL1.48%
SDY1.11%
XLV0.75%
ONEY0.75%
VOE0.72%
VHT0.64%
VFVA0.55%
ONEV0.41%
VO0.40%
VFMV0.39%
VIG0.18%
VYM0.18%
RSP0.18%
SCHV0.17%
DEM0.17%
ONEO0.16%
VTV0.16%
SPYV0.15%
IWD0.15%
VONV0.12%
IVV0.09%
ESGV0.09%
SPLG0.09%
ITOT0.08%
SCHX0.08%
SCHB0.08%
SPY0.07%
VSS0.06%
VOO0.06%
VTI0.06%
VONE0.06%
SPTM0.06%
URTH0.06%
QUS0.06%
ACWI0.04%
VT0.04%

ABT found in:

IHI16.93%
XLV2.94%
IYH2.64%
VHT2.33%
XHE1.71%
DGRW1.43%
NOBL1.34%
SDY1.07%
MGV0.75%
VIG0.69%
VFMV0.69%
SCHV0.68%
VYM0.65%
VTV0.59%
IWD0.58%
SPYV0.58%
VONV0.44%
IVV0.41%
QUS0.37%
SPLG0.37%
ESGV0.36%
ITOT0.36%
SCHX0.33%
SCHB0.30%
SPY0.27%
SPTM0.25%
VOO0.24%
URTH0.24%
VONE0.23%
VTI0.22%
ACWI0.16%
RSP0.16%
VT0.13%
ONEO0.05%

More Comparisons

Quant metrics computed from financial statements and 1,200+ trading days. Correlation is Pearson coefficient on daily log returns. Not investment advice.

BDX vs ABT: Head-to-Head Analysis

Becton, Dickinson and Company (BDX) and Abbott Laboratories (ABT) represent two companies in the Healthcare sector. In our quantitative Tale of the Tape scoring, ABT leads 5–4 across nine fundamental and risk metrics including profitability, valuation, capital efficiency, and financial health.

In terms of capital efficiency, BDX generates a return on invested capital (ROIC) of 4.2% compared to ABT's 10.1%. This suggests ABT is more effective at deploying capital to generate shareholder returns.

The 252-day rolling correlation between BDX and ABT is 0.386, indicating moderate co-movement, with some diversification value from holding both in a portfolio context.

BDX appears in 38 ETFs tracked by SecuritiesDB, while ABT appears in 34 ETFs. Investors holding broad-market ETFs may already have indirect exposure to both stocks.

Frequently Asked Questions

Which stock is the better investment, BDX or ABT?

Our quantitative analysis compares BDX and ABT across nine fundamental dimensions. ABT wins the Tale of the Tape 5–4. However, stock selection depends on your individual risk tolerance, time horizon, and portfolio context. These metrics are computed from SEC filings and market data — they are not investment recommendations.

Are BDX and ABT correlated?

The 252-day correlation between BDX and ABT is 0.386. They show moderate correlation — partially diversifying.

How is the Tale of the Tape scored?

The Tale of the Tape compares both stocks across nine categories: profitability (net margin), valuation (P/E), efficiency (ROIC), health (Piotroski F-Score), safety (Altman Z-Score), growth (revenue YoY), risk (Sharpe ratio), leverage (debt-to-equity), and cash generation (FCF yield). The stock that wins more categories takes the overall score. Lower P/E and lower debt-to-equity count as wins.